Open AccessNew developments in Sjogren’s syndrome
Author(s) -
Nishanthi Thalayasingam,
Kelly Baldwin,
Claire Judd,
WanFai Ng
Publication year - 2021
Publication title -
rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.957
H-Index - 173
eISSN - 1462-0332
pISSN - 1462-0324
DOI - 10.1093/rheumatology/keab466
Subject(s) - medicine , disease , autoimmune disease , clinical trial , lymphocytic infiltration , treatment modality , systemic disease , randomized controlled trial , intensive care medicine
SS is a chronic, autoimmune condition characterized by lymphocytic infiltration of the exocrine glands and B-cell dysfunction. Current treatment strategies are largely empirical and offer only symptomatic relief for patients. There are no proven treatments that alter disease progression or treat the systemic manifestations of disease. B-cell depletion is used in patients with systemic disease but its overall clinical efficacy has not been demonstrated in two large randomized controlled trials. Studies are now focussing on alternative strategies to target B-cells, including co-stimulation targets, with promising data. It is increasingly clear that clinical trials in SS will require patient stratification and relevant and sensitive outcome measures to identify successful treatment modalities.